JP2013517273A5 - - Google Patents

Download PDF

Info

Publication number
JP2013517273A5
JP2013517273A5 JP2012549000A JP2012549000A JP2013517273A5 JP 2013517273 A5 JP2013517273 A5 JP 2013517273A5 JP 2012549000 A JP2012549000 A JP 2012549000A JP 2012549000 A JP2012549000 A JP 2012549000A JP 2013517273 A5 JP2013517273 A5 JP 2013517273A5
Authority
JP
Japan
Prior art keywords
amino
methyl
pyrimidinyl
benzenesulfonamide
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012549000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517273A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020798 external-priority patent/WO2011088027A1/en
Publication of JP2013517273A publication Critical patent/JP2013517273A/ja
Publication of JP2013517273A5 publication Critical patent/JP2013517273A5/ja
Pending legal-status Critical Current

Links

JP2012549000A 2010-01-13 2011-01-11 化合物および方法 Pending JP2013517273A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29463710P 2010-01-13 2010-01-13
US61/294,637 2010-01-13
PCT/US2011/020798 WO2011088027A1 (en) 2010-01-13 2011-01-11 Compounds and methods

Publications (2)

Publication Number Publication Date
JP2013517273A JP2013517273A (ja) 2013-05-16
JP2013517273A5 true JP2013517273A5 (enExample) 2014-02-20

Family

ID=44304601

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012549000A Pending JP2013517273A (ja) 2010-01-13 2011-01-11 化合物および方法

Country Status (13)

Country Link
US (1) US20120329784A1 (enExample)
EP (1) EP2523559A4 (enExample)
JP (1) JP2013517273A (enExample)
KR (1) KR20120114355A (enExample)
CN (1) CN102791131A (enExample)
AU (1) AU2011205485B2 (enExample)
BR (1) BR112012017277A2 (enExample)
CA (1) CA2786999A1 (enExample)
EA (1) EA201290642A1 (enExample)
IL (1) IL220812A0 (enExample)
MX (1) MX2012008141A (enExample)
SG (1) SG182351A1 (enExample)
WO (1) WO2011088027A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844658B1 (en) * 2012-05-03 2019-03-20 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效rock1及rock2抑制劑之苯基吡唑衍生物
EP3935944A1 (en) 2013-03-15 2022-01-12 University Of Southern California, USC Stevens Compounds for the treatment of musculoskeletal diseases
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
CN104844526B (zh) * 2015-04-16 2018-08-31 温州医科大学 一种4,6-嘧啶二胺类化合物及其制备方法和应用
CN106008366A (zh) * 2016-05-25 2016-10-12 山东大学 一种利匹韦林的制备方法
JP6165373B1 (ja) * 2017-02-24 2017-07-19 タマ化学工業株式会社 ピリジン−3−スルホニルクロリドの製造方法
WO2018215801A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited Benzimidazolone derived inhibitors of bcl6
SG11202009735QA (en) 2018-04-13 2020-10-29 Cancer Research Tech Ltd Bcl6 inhibitors
CN108864052A (zh) * 2018-06-07 2018-11-23 福建医科大学 一种针对gc33-3-1抗体具有特异性识别的荧光探针的合成以及应用
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
EP4206196A1 (en) * 2021-12-29 2023-07-05 Almirall S.A. Pyrimidine substituted derivatives as tyk2 inhibitors
EP4482825A4 (en) * 2022-02-23 2026-01-28 Harvard College DDR1 and DDR2 inhibitors for the treatment of arthritis
AR128846A1 (es) 2022-03-23 2024-06-19 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg
US11891362B1 (en) * 2023-04-14 2024-02-06 King Faisal University N2,N4-disubstituted pyrimidine-2,4-diamine compounds as antibacterial agents
CN121548418A (zh) * 2023-05-23 2026-02-17 康特克斯生物科技美国公司 二环杂芳基化合物
US20240425484A1 (en) * 2023-06-02 2024-12-26 Atomwise Inc. Inhibitors of tyk2
WO2024249831A2 (en) * 2023-06-02 2024-12-05 Unogen Biotech Ltd. Triple kinase inhibitors
WO2025096550A1 (en) * 2023-10-31 2025-05-08 Twine Therapeutics, Inc. Methods of treating cardiomyopathy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW504510B (en) * 1996-05-10 2002-10-01 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives
HUP0401711A3 (en) * 2001-06-26 2009-07-28 Bristol Myers Squibb Co N-heterocyclic inhibitors of tnf-alpha and pharmaceutical compositions containing them
EP1608652A1 (en) * 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
EP1678147B1 (en) * 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
AU2005205167A1 (en) * 2004-01-16 2005-07-28 Novartis Ag 2, 4 - diaminopyrimidines and their use for inducing cardiomyogenesis
CA2553513A1 (en) * 2004-01-22 2005-08-04 Altana Pharma Ag N-4-(6- (heteo) aryl-pyrimidin-4-ylaminophenyl) -bezenesulfonamides as kinase inhibitors
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
UA109412C2 (uk) * 2005-11-01 2015-08-25 5-метил-n2-[4-(4-метилпіперазин-1-іл)феніл]-піримідин-2,4-діамін та його застосування в способі одержання сполуки
NZ567851A (en) * 2005-11-01 2011-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
AU2007257650A1 (en) * 2006-06-15 2007-12-21 Boehringer Ingelheim International Gmbh 2-anilino-4-(heterocyclic)amino-pyrimidines as inhibitors of protein kinase C-alpha
CN101589036A (zh) * 2006-12-19 2009-11-25 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的氨基嘧啶
US7947698B2 (en) * 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2014657A1 (de) * 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
EP2214486A4 (en) * 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES

Similar Documents

Publication Publication Date Title
JP2013517273A5 (enExample)
JP5555169B2 (ja) 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
RU2312860C2 (ru) Циклические ингибиторы протеинтирозинкиназ
RU2454405C2 (ru) Производные 3-пиридинкарбоксамида и 2-пиразинкарбоксамида в качестве агентов, повышающих уровень лвп-холестерина
US20120329784A1 (en) Compounds and methods
JP2013517283A5 (enExample)
ES2610158T3 (es) Nuevos inhibidores pirrólicos de S-nitrosoglutatión reductasa como agentes terapéuticos
RU2386630C2 (ru) Соединения и композиции в качестве ингибиторов протеинтирозинкиназы
JP2014511869A5 (enExample)
CA2582029A1 (en) Aryl nitrogen-containing bicyclic compounds and methods of use
RU2007100136A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
NZ597528A (en) Inhibitors of flaviviridae viruses
PT1725544E (pt) 3-[4-heterociclil-1,2,3-triazol-1-il]-n-aril-benzamidas como inibidores da produção de citocinas para o tratamento de doenças inflamatórias crónicas
CA2564355A1 (en) Protein kinase modulators and method of use
ZA200606880B (en) Diaminopyrimidines as P2X3 and P2X2/3 antagonists
ZA200505184B (en) Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
JP2013519733A5 (enExample)
JP2009537545A5 (enExample)
JP2004517925A5 (enExample)
JP2010513444A5 (enExample)
JP2003534336A5 (enExample)
CA2494695A1 (en) 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN102076671A (zh) 三唑衍生物或其盐
HRP20100283T1 (hr) Derivati n-'(1,5-difenil-1h-pirazol-3-il)sulfonamida s afinitetom za cb1 receptor
AU2006335967B2 (en) Novel heterocycles